Muscle Dysfunction in Patients With Chronic Obstructive Lung Disease (COPD): the Role of Sympathetic Activation
The objective of the project is to better understand the causes of exercise limitation, dyspnea and neurohumoral activation in patients with COPD. In particular, the investigators aim to explore the mutual interaction of neurohumoral activation and exercise limitation thereby focussing on differential effects of the peripheral muscle and the diaphragm.
Eventually the findings might influence treatment modalities. If sympathetic activation contributes to exercise limitation then drugs influencing the autonomic nervous system would be a reasonable therapeutic concept. If a reduction of sympathetic activity due to an alteration of the ergoreflex can be achieved by non-invasive ventilation this would help to improve dyspnea and exercise capacity.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||Skeletal and Respiratory Muscle Dysfunction in Patients With COPD: the Role of Sympathetic Activation|
- muscle sympathetic nerve activity (MSNA) [ Time Frame: 90 minutes ] [ Designated as safety issue: No ]In a 90 minute microneurographic measurement muscle sympathetic nerve activity is assessed.
- Arterial stiffness [ Time Frame: 90 min ] [ Designated as safety issue: No ]
- VE/VCO2 [ Time Frame: During 8-15 minutes bicycle exercise ] [ Designated as safety issue: No ]
|Study Start Date:||August 2011|
|Primary Completion Date:||November 2012 (Final data collection date for primary outcome measure)|
|No Intervention: COPD|
Experimental: COPD with non-invasive ventilation (NIV)
Starting non-invasive ventilation with the patient's own device during registration of MSNA.
|Device: non-invasive ventilation (NIV)|
|No Intervention: Healthy control subjects|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01750489
|Goettingen, Germany, 37075|
|Principal Investigator:||Stefan Andreas, Professor||Universitaetsmedizin Goettingen|